ABDICHE, Yasmina Noubia,CHO, Helen Kim,HO, Weihsien,JOOSS, Karin Ute,RAJPAL, Arvind,YOUSSEF, Sawsan
申请号：
PE2017000975
公开号：
PE20171180A1
申请日:
2015.12.02
申请国别(地区):
PE
年份:
2017
代理人:
摘要：
It refers to a single anti antibody, specifically identified as PD-1 (programmed cell death protein 1), which is characterized by a variable heavy chain (VH) region composed of CDR1, CDR2 and CDR3, including sequences selected from SEQ ID No.3 and SEQ ID No.4. SEQ ID No.5 and SEQ ID No.6 as well as a light chain variable area composed of CDR1, CDR2 and CDR3, including a sequence selected from SEQ ID No.2, SEQ ID No.7, SEQ ID No.8 and SEQ ID No.9. He also mentioned a pharmacology composer who understood that it was useful in the treatment of cancer.Se refiere a un anticuerpo antagonista aislado que se fija especificamente a PD-1 (proteina de muerte celular programada 1) caracterizado porque comprende: una region variable de cadena pesada (VH) que comprende una CDR1, CDR2 y CDR3 que tienen una secuencia seleccionada de SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5 y SEQ ID NO: 6 y una region de variable de cadena liviana (VL) que comprende una CDR1, CDR2 y CDR3 que tienen una secuencia seleccionada de SEQ ID NO: 2, SEQ ID NO: 7, SEQ ID NO:8 y SEQ ID NO: 9. Tambien se refiere a una composicion farmaceutica que lo comprende； siendo util en el tratamiento del cancer
